Clinical Trial Update: Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating riboflavin-mediated corneal crosslinking to stabilize the progression of keratoconus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconus

Drugs mentioned

• Riboflavin-mediated corneal crosslinking (riboflavin)

Snippet

Sponsor: University Hospital Freiburg | Conditions: Keratoconus | Phase 2, Phase 3 | Status: COMPLETED